URGN - CIK 0001668243
The table below shows UroGen Pharma Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -$84.89M | -$105.89M |
| Capital expenditure | $289.00K | $295.00K | $194.00K | $254.00K | $752.00K | $1.22M |
| Investing cash flow | $61.56M | -$20.61M | -$953.00K | $1.06M | $4.07M | $93.24M |
| Dividends paid | - | - | - | - | - |
UroGen Pharma Ltd. reported operating cash flow of -$162.44M for fiscal year 2025. That is down 67.9% from -$96.77M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $4.19M (FY 2016) to -$162.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | $72.32M | $16.53M |